This company has been marked as potentially delisted and may not be actively trading.

ERYTECH Pharma (ERYP) Competitors

ERYP vs. BLUW, PLX, JATT, IZTC, and ALVR

Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Blue Water Acquisition Corp. III (BLUW), Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), Invizyne Technologies (IZTC), and AlloVir (ALVR). These companies are all part of the "medical" sector.

How does ERYTECH Pharma compare to Blue Water Acquisition Corp. III?

ERYTECH Pharma (NASDAQ:ERYP) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ERYTECH Pharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Blue Water Acquisition Corp. III
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 1.1% of ERYTECH Pharma shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: In the previous week, Blue Water Acquisition Corp. III had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Blue Water Acquisition Corp. III and 0 mentions for ERYTECH Pharma. Blue Water Acquisition Corp. III's average media sentiment score of 1.79 beat ERYTECH Pharma's score of 0.00 indicating that Blue Water Acquisition Corp. III is being referred to more favorably in the news media.
Company Overall Sentiment
ERYTECH Pharma Neutral
Blue Water Acquisition Corp. III Very Positive
: Company Net Margins Return on Equity Return on Assets
ERYTECH Pharma N/A N/A N/A
Blue Water Acquisition Corp. III N/A N/A N/A
: Blue Water Acquisition Corp. III has lower revenue, but higher earnings than ERYTECH Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A
Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ERYTECH Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Overall Sentiment
ERYTECH Pharma	Neutral
Blue Water Acquisition Corp. III	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
ERYTECH Pharma	N/A	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Summary

ERYTECH Pharma and Blue Water Acquisition Corp. III tied by winning 3 of the 6 factors compared between the two stocks.

How does ERYTECH Pharma compare to Protalix BioTherapeutics?

ERYTECH Pharma (NASDAQ:ERYP) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

: In the previous week, Protalix BioTherapeutics had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score.
Company Overall Sentiment
ERYTECH Pharma Neutral
Protalix BioTherapeutics Neutral
: Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 494.06%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than ERYTECH Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ERYTECH Pharma
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Protalix BioTherapeutics
0 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
3.00
: ERYTECH Pharma has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the S&P 500.
: 1.1% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 1.9% of ERYTECH Pharma shares are owned by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: ERYTECH Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. ERYTECH Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
ERYTECH Pharma N/A N/A N/A
Protalix BioTherapeutics -21.03% -30.89% -11.74%
: Protalix BioTherapeutics has higher revenue and earnings than ERYTECH Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A
Protalix BioTherapeutics $52.74M 3.09 $8.31M -$0.09 N/A

Company	Overall Sentiment
ERYTECH Pharma	Neutral
Protalix BioTherapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ERYTECH Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
ERYTECH Pharma	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A
Protalix BioTherapeutics	$52.74M	3.09	$8.31M	-$0.09	N/A

Summary

Protalix BioTherapeutics beats ERYTECH Pharma on 8 of the 13 factors compared between the two stocks.

How does ERYTECH Pharma compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

: ERYTECH Pharma's return on equity of 0.00% beat JATT Acquisition's return on equity.
Company Net Margins Return on Equity Return on Assets
JATT Acquisition N/A -49.58% 2.84%
ERYTECH Pharma N/A N/A N/A
: In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled ERYTECH Pharma'saverage media sentiment score.
Company Overall Sentiment
JATT Acquisition Neutral
ERYTECH Pharma Neutral
: JATT Acquisition has higher earnings, but lower revenue than ERYTECH Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
JATT Acquisition N/A N/A $6.85M N/A N/A
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A
: 48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
ERYTECH Pharma	N/A	N/A	N/A

Company	Overall Sentiment
JATT Acquisition	Neutral
ERYTECH Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A

Summary

JATT Acquisition beats ERYTECH Pharma on 4 of the 6 factors compared between the two stocks.

How does ERYTECH Pharma compare to Invizyne Technologies?

ERYTECH Pharma (NASDAQ:ERYP) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

: Company Net Margins Return on Equity Return on Assets
ERYTECH Pharma N/A N/A N/A
Invizyne Technologies N/A N/A N/A
: 1.1% of ERYTECH Pharma shares are held by institutional investors. 1.9% of ERYTECH Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, Invizyne Technologies had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for ERYTECH Pharma. ERYTECH Pharma's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.
Company Overall Sentiment
ERYTECH Pharma Neutral
Invizyne Technologies Neutral
: Invizyne Technologies has lower revenue, but higher earnings than ERYTECH Pharma.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A
Invizyne Technologies N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
ERYTECH Pharma	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A

Company	Overall Sentiment
ERYTECH Pharma	Neutral
Invizyne Technologies	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

ERYTECH Pharma beats Invizyne Technologies on 3 of the 4 factors compared between the two stocks.

How does ERYTECH Pharma compare to AlloVir?

AlloVir (NASDAQ:ALVR) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

: In the previous week, AlloVir had 1 more articles in the media than ERYTECH Pharma. MarketBeat recorded 1 mentions for AlloVir and 0 mentions for ERYTECH Pharma. AlloVir's average media sentiment score of 0.00 equaled ERYTECH Pharma'saverage media sentiment score.
Company Overall Sentiment
AlloVir Neutral
ERYTECH Pharma Neutral
: AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500.
: ERYTECH Pharma's return on equity of 0.00% beat AlloVir's return on equity.
Company Net Margins Return on Equity Return on Assets
AlloVir N/A -71.03% -61.27%
ERYTECH Pharma N/A N/A N/A
: 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: ERYTECH Pharma has higher revenue and earnings than AlloVir.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AlloVir N/A N/A -$190.42M -$20.23 N/A
ERYTECH Pharma $32.66M 3.24 -$240K N/A N/A

Company	Overall Sentiment
AlloVir	Neutral
ERYTECH Pharma	Neutral

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
ERYTECH Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
ERYTECH Pharma	$32.66M	3.24	-$240K	N/A	N/A

Summary

ERYTECH Pharma beats AlloVir on 5 of the 8 factors compared between the two stocks.

Get ERYTECH Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERYP vs. The Competition

Export

Metric	ERYTECH Pharma	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$105.77M	$328.34M	$6.28B	$11.90B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	N/A	N/A	29.17	27.35
Price / Sales	3.24	178.97	525.50	85.51
Price / Cash	N/A	22.44	43.42	54.56
Price / Book	3.88	4.75	9.82	6.79
Net Income	-$240K	-$132.96M	$3.55B	$332.68M

ERYTECH Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERYP ERYTECH Pharma	N/A	$3.10 flat	N/A	N/A	$105.77M	$32.66M	N/A	49
BLUW Blue Water Acquisition Corp. III	N/A	$10.26 0.0%	N/A	+6.5%	$288.37M	N/A	N/A	2	Positive News
PLX Protalix BioTherapeutics	2.2259 of 5 stars	$2.13 -0.9%	$12.00 +463.4%	-26.0%	$171.62M	$52.74M	N/A	200	News Coverage
JATT JATT Acquisition	N/A	$10.75 +2.4%	N/A	+632.7%	$83.85M	N/A	N/A	3
IZTC Invizyne Technologies	N/A	$10.35 +0.2%	N/A	-8.9%	$64.71M	N/A	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERYP) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ERYTECH Pharma (ERYP) Competitors

ERYP vs. BLUW, PLX, JATT, IZTC, and ALVR

How does ERYTECH Pharma compare to Blue Water Acquisition Corp. III?

Summary

How does ERYTECH Pharma compare to Protalix BioTherapeutics?

Summary

How does ERYTECH Pharma compare to JATT Acquisition?

Summary

How does ERYTECH Pharma compare to Invizyne Technologies?

Summary

How does ERYTECH Pharma compare to AlloVir?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP vs. The Competition

ERYTECH Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ERYTECH Pharma (ERYP) Competitors

ERYP vs. BLUW, PLX, JATT, IZTC, and ALVR

How does ERYTECH Pharma compare to Blue Water Acquisition Corp. III?

Summary

How does ERYTECH Pharma compare to Protalix BioTherapeutics?

Summary

How does ERYTECH Pharma compare to JATT Acquisition?

Summary

How does ERYTECH Pharma compare to Invizyne Technologies?

Summary

How does ERYTECH Pharma compare to AlloVir?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP vs. The Competition

ERYTECH Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools